We serve DL-Ornithine Monohydrochloride CAS:1069-31-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
DL-Ornithine Monohydrochloride
CAS RN: 1069-31-4
| Solubility in water | Colorless & clear (c=5) |
| Loss on drying | Not more than 0.3% |
| Residue on ignition (as sulfate) | Not more than 0.1% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 10μg) |
| Assay | 98.5%～101.0% |
Contact us for information like DL-Ornithine Monohydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DL-Ornithine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DL-Ornithine Monohydrochloride Use and application,DL-Ornithine Monohydrochloride technical grade,usp/ep/jp grade.
Related News: The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.2-Chloro-5-nitropyridine manufacturer The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.4-Amino-3-nitrobenzotrifluoride supplier The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.trans-2-Heptenal vendor The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.
